OnKure Therapeutics (OKUR) Price & Analysis

Compare

313 Followers

OKUR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.70 - $20.00

Previous CloseN/A

Volume8.61K

Average Volume (3M)68.73K

Market Cap

$27.02M

Enterprise Value-$50.26M

Total Cash (Recent Filing)$83.37M

Total Debt (Recent Filing)$823.00K

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Aug 06, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.19

Shares Outstanding12,823,872

10 Day Avg. Volume65,919

30 Day Avg. Volume68,728

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.86

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit116.62

Enterprise Value/Ebitda0.82

Forecast

1Y Price Target

$26.50

Price Target Upside1004.17% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Analyst RatingsOnKure Therapeutics, Inc. received a 'Buy' rating from analysts.

Drug DevelopmentOnKure's molecule OKI-219 appears to have best-in-class tolerability, observing only Grade 1 TRAEs even at the highest dose and no discontinuations for safety.

Financial StabilityCash and cash equivalents were reported at $96.7 million, which the company expects to provide a runway into 4Q26.

Bears Say

Investor ConcernsInvestors have had questions on the selectivity and potency across common PIK3CA mutations of current clinical 'pan-mutant' PI3Ka inhibitors in development.

Market CompetitionThe rapid development of next-generation drugs in the HR+/HER2- breast cancer space is challenging the relevance of initially approved treatments.

OnKure Therapeutics News

OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)

“We are encouraged by the continued progress in the development of our lead asset, OKI-219, as we have...

3d ago

OKUR

OnKure Therapeutics Advances Cancer Drug Development

Reneo Pharmaceuticals Inc ( ($OKUR) ) has released its Q2 earnings. Here is a breakdown of the information...

3d ago

OKUR

OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating

OnKure Therapeutics (OKUR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

OKUR

OnKure Therapeutics Updates on PI3Kα Inhibitor Progress

OnKure Therapeutics ( ($OKUR) ) has shared an announcement. On June 26, 2025, OnKure Therapeutics released an updated...

2M ago

OKUR

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position

OnKure Therapeutics (OKUR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

2M ago

OKUR

OnKure Elects Directors at Annual Stockholder Meeting

OnKure Therapeutics ( ($OKUR) ) just unveiled an announcement. On May 27, 2025, OnKure Therapeutics held its Annual...

3M ago

OKUR

One new option listing and nine option delistings on May 19th

New option listings for May 19th include Jacobs Engineering (J). Option delistings effective May 19th include BrainStorm (BCLI),...

3M ago

DFS

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on OnKure Therapeutics (OKUR – Research Report) and...

3M ago

OKUR

OnKure Therapeutics Reports Q1 2025 Progress and Financials

Reneo Pharmaceuticals Inc ( ($OKUR) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

OKUR

OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)

“OnKure looks to define a new standard of performance for precision targeted agents. We designed OKI-219 and our...

3M ago

OKUR

OnKure Therapeutics sees cash runway into 4Q26

Cash and cash equivalents were approximately $96.7 million as of March 31, 2025. Published first on TheFly –...

3M ago

OKUR

OnKure Therapeutics initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of OnKure Therapeutics (OKUR) with an Outperform rating. OnKure “has a lot to prove”...

4M ago

OKUR

OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on OnKure Therapeutics (OKUR) to $34 from $40 and keeps a...

5M ago

OKUR

Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025

JonesTrading analyst Soumit Roy has maintained their bullish stance on OKUR stock, giving a Buy rating on March...

5M ago

OKUR

OKUR FAQ

What was OnKure Therapeutics’s price range in the past 12 months?

OnKure Therapeutics lowest stock price was $1.70 and its highest was $20.00 in the past 12 months.

What is OnKure Therapeutics’s market cap?

OnKure Therapeutics’s market cap is $27.02M.

When is OnKure Therapeutics’s upcoming earnings report date?

OnKure Therapeutics’s upcoming earnings report date is Aug 06, 2025 which is 9 days ago.

How were OnKure Therapeutics’s earnings last quarter?

OnKure Therapeutics released its earnings results on May 06, 2025. The company reported -$1.19 earnings per share for the quarter, beating the consensus estimate of -$1.38 by $0.19.

Is OnKure Therapeutics overvalued?

According to Wall Street analysts OnKure Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OnKure Therapeutics pay dividends?

OnKure Therapeutics does not currently pay dividends.

What is OnKure Therapeutics’s EPS estimate?

OnKure Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OnKure Therapeutics have?

OnKure Therapeutics has 12,823,872 shares outstanding.

What happened to OnKure Therapeutics’s price movement after its last earnings report?

OnKure Therapeutics reported an EPS of -$1.19 in its last earnings report, beating expectations of -$1.38. Following the earnings report the stock price went up 20%.

Which hedge fund is a major shareholder of OnKure Therapeutics?

Currently, no hedge funds are holding shares in OKUR

OnKure Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-90.56%

Trailing 12-Months

Asset Growth

18.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

OnKure Therapeutics

OnKure Therapeutics (OKUR) is a clinical-stage biopharmaceutical company specializing in the discovery and development of targeted oncology therapies. The company focuses on creating innovative small molecule inhibitors that modulate key oncogenic pathways, aiming to provide effective treatments for cancer patients. OnKure's core products are primarily centered around its proprietary drug candidates designed to address unmet medical needs in oncology.

OnKure Therapeutics (OKUR) Earnings & Revenues

Historic Earnings Reports

OKUR Stock 12 Month Forecast

Average Price Target

$26.50

▲(1004.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","66":"$66","17.25":"$17.25","33.5":"$33.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,17.25,33.5,49.75,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.2,4.492307692307692,6.7846153846153845,9.076923076923077,11.369230769230768,13.66153846153846,15.953846153846154,18.246153846153845,20.538461538461537,22.830769230769228,25.12307692307692,27.415384615384614,29.707692307692305,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.2,4.069230769230769,5.938461538461539,7.8076923076923075,9.676923076923078,11.546153846153846,13.415384615384614,15.284615384615385,17.153846153846153,19.02307692307692,20.892307692307693,22.76153846153846,24.63076923076923,{"y":26.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.2,3.6461538461538465,5.092307692307692,6.538461538461538,7.984615384615385,9.430769230769231,10.876923076923077,12.323076923076922,13.76923076923077,15.215384615384615,16.661538461538463,18.107692307692307,19.553846153846152,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.5,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.4,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1714521600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.95,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >